| Topical rapamycin for treating facial angiofibromas associated with tuberous sclerosis complex in people 6 years and over [ID6391] | Technology appraisal guidance | TBC |
| Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309] | Technology appraisal guidance | |
| Treatments for non-small-cell lung cancer [ID6234] | Technology appraisal guidance | TBC |
| Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [ID6165] | Technology appraisal guidance | TBC |
| Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227] | Technology appraisal guidance | TBC |
| Upadacitinib for treating giant cell arteritis [ID6299] | Technology appraisal guidance | |
| Vanzacaftor–tezacaftor–deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people aged 6 years and over [ID6372] | Technology appraisal guidance | |
| Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell lung cancer [ID1277] | Technology appraisal guidance | TBC |
| Venetoclax with azacitidine for untreated high-risk myelodysplastic syndromes [ID6314] | Technology appraisal guidance | TBC |
| Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia when there is no 17p deletion or TP53 mutation and FCR (fludarabine, cyclophosphamide, rituximab) or BR (bendamustine, rituximab) are suitable (MA partial review of TA663) [ID6291] | Technology appraisal guidance | |